Market Overview

Rodman & Renshaw Reiterates Outperform Rating on Agenus


Rodman & Renshaw is out with a research report this afternoon, where it reiterates its Outperform rating on Agenus Inc. (NASDAQ: AGEN); it has a $2.00 price target on the stock.

The R&R analysts cited the company's recent ASCO data, which updated survival results from an ongoing Phase 2 trial evaluating Prophage G-200, a patient-specific heat shock protein-based therapeutic vaccine, for the treatment of recurrent high-grade gliomas.

As for valuation, the analysts remarked, “We are reiterating our Market Outperform / Speculative Risk rating on Agenus with a 12-month target price of $2, based on a comparable company analysis to value the oncology programs in combination with a net present value analysis for the potential contribution of future QS-21 royalty revenue to the company's valuation.”


Related Articles (AGEN)

View Comments and Join the Discussion!

Posted-In: Rodman & RenshawAnalyst Color Price Target Analyst Ratings

Latest Ratings

SMEDLake StreetInitiates Coverage On10.0
CHWYCleveland ResearchInitiates Coverage On60.0
TECHStephens & Co.Downgrades273.0
EOGWolfe ResearchDowngrades54.0
MURWolfe ResearchDowngrades10.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at